MG1106 (rituximab biosimilar) / GC Biopharma - LARVOL DELTA

What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma? (YouTube) - "During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the Lymphoma Hub was pleased to speak with Anna Sureda...She highlights that the introduction of new drugs like rituximab have had an impact on reducing the number of allogenic transplants occurring...."

Video

IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies (clinicaltrials.gov) - P4; N=50; Active, not recruiting; Sponsor: Seoul National University Hospital; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2021 ➔ Dec 2021; Trial primary completion date: Jan 2021 ➔ Dec 2021

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Renal Disease • Transplantation

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin (clinicaltrials.gov) - P1/2; N=9; Active, not recruiting; Sponsor: Green Cross LabCell Corporation; Recruiting ➔ Active, not recruiting; N=100 ➔ 9; Trial completion date: Dec 2022 ➔ Oct 2020

Clinical • Combination therapy • Enrollment change • Enrollment closed • Trial completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin (clinicaltrials.gov) - P1/2; N=100; Recruiting; Sponsor: Green Cross LabCell Corporation; Trial primary completion date: Oct 2019 ➔ Apr 2020

Clinical • Combination therapy • Trial primary completion date

Randomized Controlled Trial of IVIG/Rituximab Versus Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies (clinicaltrials.gov) - P4; N=50; Recruiting; Sponsor: Seoul National University Hospital

New P4 trial